Project Grant R00HL181187
Award Date 9/1/26
Completion Date 7/31/29
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Duke University $215,504 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025, to fund research on epithelial cell-mediated fibroblast activation through CTHRC1-TGFB signaling in fibrotic lung diseases. The research investigates mechanisms of fibroblast activation in bronchiolitis obliterans and idiopathic pulmonary fibrosis. Aim 1 evaluates airway epithelial cell-fibroblast interactions contributing to...
- The National Heart Lung and Blood Institute awarded the Regents of the University of Michigan $134,439 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support mentoring in translational interstitial lung disease research. The award funds development of protein-based biomarkers for patients with fibrotic interstitial lung disease (ILD) through two primary objectives: deriving and validating a proteomic biomarker to predict ILD in patients presenting with...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $249,000 under the Cardiovascular Diseases Research program (CFDA 93.837) on April 2, 2026, to support research on the role of subpleural fibroblasts in pulmonary fibrosis progression. The funded research investigates idiopathic pulmonary fibrosis (IPF), which begins with scar tissue buildup at the lung edges and advances centrally. The project applies lineage tracing, mouse modeling, and...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1,151,498 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on lung epithelial development and regeneration. The research aims to restore epithelial integrity and prevent end-stage lung diseases such as idiopathic pulmonary fibrosis by understanding how the lung epithelium develops in embryos and regenerates following injury....
- The National Heart, Lung, and Blood Institute awarded the Trustees of Boston University $712,630 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate functional heterogeneity of alveoli and early responses to airborne agents. The recipient will develop and apply the Crystal Ribcage, a novel intravital imaging platform, to visualize real-time, high-resolution dynamics of the intact, ventilating lung. The research will define the anatomy, physiology,...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $1,357,964 on August 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to discover prognostic biomarkers of early pulmonary fibrosis and develop secondary prevention strategies. The research identifies genetic, molecular, and environmental biomarkers that trigger and predict progression of fibrotic interstitial lung abnormalities (FILAs)...
- The National Heart, Lung, and Blood Institute awarded The Trustees Of The University Of Pennsylvania $1,624,110 on June 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of lung repair and regeneration following acute injury. The project examines dysplastic versus euplastic repair pathways in lung tissue. The research addresses how basal stem cells migrate into the alveolar niche after injury, displacing AT2 progenitor cells and creating an...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $768,414 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct multi-omic profiling research examining the relationship between idiopathic pulmonary fibrosis and cardiovascular disease. The research identifies shared molecular mechanisms linking pulmonary fibrosis and cardiovascular disease through blood-based and tissue analysis. The project defines shared...
- The National Heart Lung and Blood Institute awarded Northwestern University $104,928 for a Project Grant (K99HL188111) on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research targeting lipid signaling pathways in perivascular interstitial macrophages as a therapeutic strategy for pulmonary fibrosis. The investigator will use single-cell spatial transcriptomics and RNA sequencing to characterize how perivascular interstitial macrophages...
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $717,680 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate immune epithelial niche mechanisms underlying post-viral lung fibrosis. The research examines how anti-viral CD8+ T cell immunity, specifically interferon-gamma signaling and macrophage-derived interleukin-1 beta secretion, impairs alveolar epithelial repair following severe respiratory viral infections. The...